… hyperglycemia, hypertension and dyslipidemia, increase the … in the case of persistent side
effects, as above reported. Notably, … on the RAS due to persistent side effects was low and was …

… to control diabetes, hypertension, and dyslipidemia were all lower after surgery (P < 0.001). …
, have type 2 diabetes (1), and ∼40% have obesity (2). Obesity and type 2 diabetes cause …

… , dyslipidemia, hypertension, and type 2 diabetes. See Table 1 for the search method utilized
in PubMed/MEDLINE. This search method was used in July of 2019 to translate the search …

… About 30–60% of Western diabetes patients are dyslipidemic (hypertriglyceridemia, small
… Most importantly, except for pioglitazone (having a limited use due to side effects) and GLP1 …

… of obesity and type 2 DM (T2DM) have a mutual effect on each other. For example, anti-obesity
drugs can be anti-diabetic to some extent, and some anti-diabetic medicines, in contrast, …

… , their use is often associated with severe side effects, therefore the development of new
drug … in the treatment of type 2 diabetic patients. A significant inhibitory effect on α-glucosidase …

… Thus, EE might ultimately relieve the symptoms of hyperglycemia and hyperlipidemia as
well as heart tissue damage through lowering the levels of BCAA and AAA in the gut. …

… participants might be the results of the medical treatment for type 2 diabetes or dyslipidemia.
… A study from Korea suggested that Asians might be more susceptible to the adverse effects …

… that DPN secondary to type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) …
10% to 50% for both type 1 diabetes (T1DM) and type 2 diabetes (T2DM). The DPN annual …

… Background: Insulin secretory agents are commonly used to treat type 2 diabetes. However,
traditional insulin secretory agents such as sulfonylureas and glinides have side effects of …